Solutions
About Us
Insights
Careers

Value-based pricing: a potential solution to difficult pricing discussions and payers’ negotiations. Tremblay G, Poirier A, Monfort L., J Med Econ. 2024

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. Weisel K, Dimopoulos MA, Beksac M, Leleu X, Richter J, Heeg B, Patel S, Majer I, McFadden I, Mikhael, J. Leuk Lymphoma. 2024

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P., Leuk Lymphoma. 2024

Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis. Amonkar MM, Abderhalden LA, Fox GE, Frederickson AM, Grira T, Gozman A, Malhotra U, Malbecq W, Akers KG., Future Oncol. 2024

Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W., Arthritis Res Ther. 2024

A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke. Kasner SE, Sondergaard L, Nakum M, Gomez Montero M, Hashim M, Landaas EJ., J Med Econ. 2024

Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis. Pacis S, Bolzani A, Heuck A, Gossens K, Kruse M, Fritz B, Maywald U, Wilke T, Kunz C., Oncol Ther. 2024

Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data. Schuster AK, Leisle L, Picker N, Bubendorfer-Vorwerk H, Lewis P, Hahn P, Wasem J, Finger RP., Ophthalmol Ther. 2024

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. D’Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S., Eur J Gastroenterol Hepatol. 2024

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. Raad A, Rizzo M, Appiah K, Kearns I, Hernandez L., Pharmacoeconomics. 2024